Appendix 3Y Change of Director's Interest Notice
Appendix 3Y
Change of Director's Interest Notice
Rule 3.19A.2
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
|
Name of entity MGC Pharmaceuticals Ltd
|
|
ABN 30 116 800 269
|
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
|
Name of Director
|
Ross Grant Thomas Walker
|
|
Date of last notice
|
16 February 2016
|
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.
|
Direct or indirect interest
|
Indirect
|
|
Nature of indirect interest (including registered holder)
Note: Provide details of the circumstances giving rise to the relevant interest.
|
Ross G T Walker Pty Ltd Director and Shareholder
|
|
Date of change
|
23 December 2016
|
|
No. of securities held prior to change
|
Nil
|
|
Class
|
Performance Rights
|
|
Number acquired
|
4,000,000
|
|
Number disposed
|
0
|
|
Value/Consideration
Note: If consideration is non-cash, provide details and estimated valuation
|
Nil cash -issued as part of the remuneration package as set out in the Notice of Annual General Meeting dated 20/10/2016 and approved at the meeting held 29/11/2016.
Estimated Valuation: $164,000 based on the share price of $0.041 on the date of issue, this figure assumes all the performance milestones are met in full.
|
|
No. of securities held after change
|
Ross G T Walker Pty Ltd 4,000,000 Performance Rights
|
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y
Change of Director's Interest Notice
|
|
|
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back
|
Performance Rights were issued following approval at the Company's shareholder meeting held on 29/11/2016. The terms and conditions are detailed in the Notice of Meeting dated 20/10/2016 (Schedule 1).
|
Part 2 - Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.
|
Detail of contract
|
N/A
|
|
Nature of interest
|
|
Name of registered holder (if issued securities)
|
|
Date of change
|
|
No. and class of securities to which interest related prior to change
Note: Details are only required for a contract in relation to which the interest has changed
|
|
Interest acquired
|
|
Interest disposed
|
|
Value/Consideration
Note: If consideration is non-cash, provide details and an estimated valuation
|
|
Interest after change
|
Part 3 - +Closed period
|
Were the interests in the securities or contracts detailed
above traded during a +closed period where prior written clearance was required?
|
N/A
|
|
If so, was prior written clearance provided to allow the trade to proceed during this period?
|
|
If prior written clearance was provided, on what date was this provided?
|
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 01/01/2011